Mitsukane Yoshinaga
Taisho Pharmaceutical Co.
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Mitsukane Yoshinaga.
The Journal of Nuclear Medicine | 2017
Kazumi Koga; Yuji Nagai; Masayuki Hanyu; Mitsukane Yoshinaga; Shigeyuki Chaki; Norikazu Ohtake; Satoshi Ozaki; Ming-Rong Zhang; Tetsuya Suhara; Makoto Higuchi
Vasopressin 1B receptors (V1BRs) are abundantly expressed in the pituitary, and in vivo PET of V1BRs was recently enabled by our development of a specific radioligand, 11C-TASP0434299, derivatized from pyridopyrimidin-4-one. Here, we identified a novel pyridopyrimidin-4-one analog, N-tert-butyl-2-[2-(6-11C-methoxypyridine-2-yl)-6-[3-(morpholin-4-yl)propoxy]-4-oxopyrido[2,3-d]pyrimidin-3(4H)-yl]acetamide (11C-TASP0410699, hereafter referred to as 11C-TASP699), as a potent V1BR radioligand producing a higher image contrast for the target than 11C-TASP0434299. Methods: In vitro properties of TASP699 were assessed by assaying its affinity for human V1BR and its selectivity for off-target molecules. Radioactive uptake in the pituitary was analyzed using PET in rhesus monkeys after intravenous administration of 11C-TASP699. Serial doses of a selective V1BR antagonist, 2-[2-(3-chloro-4-fluorophenyl)-6-[3-(morpholin-4-yl)propoxy]-4-oxopyrido[2,3-d]pyrimidin-3(4H)-yl]-N-isopropylacetamide hydrochloride (TASP0390325), were administered before the radioligand injection. Autoradiographic labeling of monkey pituitary slices with 11C-TASP699 was conducted with or without nonradioactive V1BR antagonists. Results: The half maximal inhibitory concentration (IC50) of TASP699 for human V1BRs (0.165 nM) was lower than that of TASP0434299 (0.526 nM), whereas its IC50 values for off-target molecules exceeded 1 μM. PET imaging in monkeys demonstrated that the peak pituitary uptake of 11C-TASP699 was almost equivalent to that of 11C-TASP0434299 and that pretreatment with TASP0390325 inhibited the retention of 11C-TASP699 in a dose-dependent manner, inducing nearly full occupancy at 0.3 mg/kg. Specific radioligand binding was determined as a specific–to–nondisplaceable uptake ratio at equilibrium using radioactivity retentions at 60 min in baseline and blocking studies. This ratio for 11C-TASP699 was approximately 2.5-fold greater than that of 11C-TASP0434299. A reversed-phase high-performance liquid chromatography study identified the parent and polar radiometabolites. Affinities of 2 predicted metabolite candidates for V1BRs were more than 10 times weaker than that of the parent. Intense autoradiographic labeling of the anterior pituitary with 11C-TASP699 was inhibited with TASP0390325 in a concentration-dependent manner. Conclusion: 11C-TASP699 yielded PET images of pituitary V1BRs with a higher contrast than 11C-TASP0434299, supporting the applicability of 11C-TASP699 in the assessment of neuropsychiatric diseases and dose findings for test drugs in clinical trials.
Journal of Pharmacology and Experimental Therapeutics | 2016
Kazumi Koga; Mitsukane Yoshinaga; Yoshikatsu Uematsu; Yuji Nagai; Naoki Miyakoshi; Yoko Shimoda; Masayuki Fujinaga; Takafumi Minamimoto; Ming-Rong Zhang; Makoto Higuchi; Norikazu Ohtake; Tetsuya Suhara; Shigeyuki Chaki
A novel pyridopyrimidin-4-one derivative, N-tert-butyl-2-[2-(3-methoxyphenyl)-6-[3-(morpholin-4-yl)propoxy]-4-oxopyrido[2,3-d]pyrimidin-3(4H)-yl]acetamide (TASP0434299), was characterized as a radioligand candidate for arginine vasopressin 1B (V1B) receptor. TASP0434299 exhibited high binding affinities for human and rat V1B receptors with IC50 values of 0.526 and 0.641 nM, respectively, and potent antagonistic activity at the human V1B receptor with an IC50 value of 0.639 nM without apparent binding affinities for other molecules at 1 μM. [3H]TASP0434299 bound to membranes expressing the human V1B receptor as well as those prepared from the rat anterior pituitary in a saturable manner. The binding of [3H]TASP0434299 to the membranes was dose-dependently displaced by several ligands for the V1B receptor. In addition, the intravenous administration of [3H]TASP0434299 to rats produced a saturable radioactive accumulation in the anterior pituitary where the V1B receptor is enriched, and it was dose-dependently blocked by the oral administration of 2-[2-(3-chloro-4-fluorophenyl)-6-[3-(morpholin-4-yl)propoxy]-4-oxopyrido[2,3-d]pyrimidin-3(4H)-yl]-N-isopropylacetamide hydrochloride, a V1B receptor antagonist, indicating that [3H]TASP0434299 can be used as an in vivo radiotracer to measure the occupancy of the V1B receptor. Finally, the intravenous administration of [11C]TASP0434299 provided positron emission tomographic images of the V1B receptor in the pituitary in an anesthetized monkey, and the signal was blocked by pretreatment with an excess of unlabeled TASP0434299. These results indicate that radiolabeled TASP0434299 is the first radioligand to be capable of quantifying the V1B receptor selectively in both in vitro and in vivo studies and will provide a clinical biomarker for determining the occupancy of the V1B receptor during drug development or for monitoring the levels of the V1B receptor in diseased conditions.
Bioorganic & Medicinal Chemistry | 2008
Hiroshi Ohta; Tomoko Ishizaka; Makoto Tatsuzuki; Mitsukane Yoshinaga; Izumi Iida; Tomomi Yamaguchi; Yasumitsu Tomishima; Nobuko Futaki; Yoshihisa Toda; Shuji Saito
Bioorganic & Medicinal Chemistry Letters | 2007
Hiroshi Ohta; Tomoko Ishizaka; Makoto Tatsuzuki; Mitsukane Yoshinaga; Izumi Iida; Yasumitsu Tomishima; Yoshihisa Toda; Shuji Saito
Bioorganic & Medicinal Chemistry Letters | 2007
Hiroshi Ohta; Tomoko Ishizaka; Mitsukane Yoshinaga; Aki Morita; Yasumitsu Tomishima; Yoshihisa Toda; Shuji Saito
Archive | 2008
Takeshi Kuwada; Dai Nozawa; Tomoko Ishizaka; Mitsukane Yoshinaga; Kensei Yoshikawa
Archive | 2011
Takeshi Kuwada; Mitsukane Yoshinaga; Tomoko Ishizaka; Daisuke Wakasugi; Shin-Ichi Shirokawa; Nobutaka Hattori; Youichi Shimazaki; Naoki Miyakoshi
Archive | 2017
Daisuke Wakasugi; Mitsukane Yoshinaga; Naoki Miyakoshi; Nobutaka Hattori; Shin-Ichi Shirokawa; Takeshi Kuwada; Tomoko Ishizaka; Youichi Shimazaki
Archive | 2013
Mitsukane Yoshinaga; Tomoko Ishizaka; Daisuke Wakasugi; Shin-Ichi Shirokawa; Nobutaka Hattori; Shuhei Kashiwa; Takeshi Kuwada; Youichi Shimazaki
Archive | 2011
Takeshi Kuwada; Mitsukane Yoshinaga; Tomoko Ishizaka; Daisuke Wakasugi; Shin-Ichi Shirokawa; Nobutaka Hattori; Youichi Shimazaki; Naoki Miyakoshi